|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:associated_with
|
gptkb:Bayer_Health_Care
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:atccode
|
L01 XE05
|
|
gptkbp:available_in
|
many countries
|
|
gptkbp:chemical_formula
|
C21 H16 Cl F2 N3 O3 S
|
|
gptkbp:clinical_trial
|
Phase III
NCT00083766
NCT00413625
NCT00413638
NCT00413651
NCT00413664
NCT00413677
NCT00413690
NCT00413703
NCT00413716
NCT00413729
|
|
gptkbp:clinical_use
|
oncology
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
lactation
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:drug_interactions
|
gptkb:simvastatin
gptkb:warfarin
gptkb:atorvastatin
|
|
gptkbp:effective_date
|
gptkb:2005
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:healthcare
|
gptkb:2005
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nexavar
|
|
gptkbp:indication
|
gptkb:hepatocellular_carcinoma
advanced renal cell carcinoma
|
|
gptkbp:ingredients
|
gptkb:sorafenib
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:lifespan
|
approximately 25 hours
|
|
gptkbp:manufacturer
|
gptkb:Bayer
|
|
gptkbp:marketed_as
|
gptkb:Sorafenib
|
|
gptkbp:mechanism_of_action
|
inhibitor of multiple kinases
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:previous_name
|
gptkb:sorafenib_tosylate
|
|
gptkbp:price
|
varies by country
|
|
gptkbp:research_areas
|
cancer therapy
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
hypertension
diarrhea
skin rash
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:symbolism
|
gptkb:2006
|
|
gptkbp:used_for
|
treatment of kidney cancer
treatment of liver cancer
|
|
gptkbp:bfsParent
|
gptkb:Bayer_Pharmaceuticals_Division
gptkb:Bayer_Health_Care
|
|
gptkbp:bfsLayer
|
6
|